Compare PRPL & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRPL | ASRT |
|---|---|---|
| Founded | 2010 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.8M | 75.1M |
| IPO Year | N/A | 1997 |
| Metric | PRPL | ASRT |
|---|---|---|
| Price | $0.77 | $0.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $1.00 | ★ $3.00 |
| AVG Volume (30 Days) | 273.1K | ★ 313.9K |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $457,012,000.00 | $137,354,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.69 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 9.22 |
| 52 Week Low | $0.56 | $0.51 |
| 52 Week High | $1.29 | $1.01 |
| Indicator | PRPL | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 44.88 | 41.47 |
| Support Level | $0.73 | $0.75 |
| Resistance Level | $0.80 | $0.80 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 19.30 | 23.22 |
Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms and other products. The Company has one reportable segment that operates an omni-channel distribution which allows the Company to offer a seamless shopping experience to its customers across multiple sales channels. It sells its products through its direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.